Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy

Lymphoma
09/10/2020

Blood Adv. 2020 Oct 13;4(19):4869-4872. doi: 10.1182/bloodadvances.2020002292.

NO ABSTRACT